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Reproducibility	  of	  in	  vivo	  research	  using	  the	  mouse	  as	  a	  model	  organism	  is	  
dependent	  on	  many	  factors	  including	  experimental	  design,	  strain	  or	  stock,	  
experimental	  protocols,	  and	  methods	  of	  data	  evaluation.	  Gross	  and	  
histopathology	  are	  often	  the	  endpoints	  of	  such	  studies	  and	  there	  is	  increasing	  
concern	  about	  the	  accuracy	  and	  reproducibility	  of	  diagnoses	  in	  the	  literature.	  In	  
order	  to	  reproduce	  histopathologic	  results,	  the	  pathology	  protocol,	  including	  
necropsy	  methods	  and	  slide	  preparation,	  should	  be	  followed	  by	  interpretation	  of	  
the	  slides	  by	  a	  pathologist	  familiar	  with	  reading	  mouse	  slides	  and	  familiar	  with	  the	  
consensus	  medical	  nomenclature	  used	  in	  mouse	  pathology.	  Likewise,	  it	  is	  
important	  that	  pathologists	  are	  consulted	  as	  reviewers	  of	  manuscripts	  where	  
histopathology	  is	  a	  key	  part	  of	  the	  investigation.	  The	  absence	  of	  pathology	  
expertise	  in	  planning,	  executing,	  and	  reviewing	  in	  vivo	  research	  using	  mice	  leads	  
to	  questionable	  pathology-­‐based	  findings	  and	  conclusions	  from	  studies,	  even	  in	  
high	  impact	  journals.	  We	  discuss	  the	  various	  aspects	  of	  this	  growing	  problem,	  give	  
some	  examples	  from	  the	  literature,	  and	  suggest	  solutions.	  	  
	  
Histopathological	  descriptions	  of	  the	  frequency	  and	  nature	  of	  lesions	  and	  disease	  entities	  are	  
very	  often	  the	  endpoints	  in	  biomedical	  research	  conducted	  in	  model	  organisms	  such	  as	  the	  
mouse.	  In	  contrast	  to	  clinical	  pathology	  where	  endpoints	  are	  usually	  assessed	  using	  biochemical	  
and	  molecular	  assays,	  histopathological	  assessment,	  whilst	  using	  molecular	  markers	  and	  
imaging	  as	  adjunct	  qualitative	  and	  quantitative	  techniques,	  is	  highly	  dependent	  on	  the	  
individual	  expertise	  of	  trained	  expert	  pathologists,	  not	  only	  in	  recognizing	  lesions	  but	  also	  in	  
their	  knowledge	  of	  the	  background	  diseases	  of	  the	  mice	  and	  understanding	  of	  the	  meaning	  of	  
the	  pattern	  of	  disease	  in	  the	  whole	  mouse1-­‐4.	  	  Reproducibility	  of	  histopathological	  endpoints	  
therefore	  depends	  on	  the	  implementation	  of	  a	  common	  standardized	  vocabulary,	  competent	  
work-­‐up,	  and	  an	  in-­‐depth	  knowledge	  of	  the	  mouse	  strains	  under	  investigation	  so	  that,	  for	  
example,	  background	  lesions	  are	  not	  mistaken	  for	  those	  which	  are	  experimentally	  induced.	  
Such	  knowledge	  is	  critical	  in	  the	  design	  of	  experiments,	  as	  well	  as	  in	  understanding	  the	  impact	  
of	  husbandry,	  the	  microbiome,	  and	  diet	  on	  the	  interpretation	  of	  results2,	  5.	  
	  In	  recent	  years	  increasing	  concern	  has	  been	  expressed	  by	  funding	  agencies	  and	  scientific	  
communities	  alike	  about	  the	  lack	  of	  reproducibility	  of	  experiments	  in	  the	  biomedical	  domain.	  
Attention	  was	  initially	  drawn	  to	  this	  by	  pharmaceutical	  companies	  which	  rely	  on	  preclinical,	  
precompetitive	  research	  for	  drug	  development	  pipelines6-­‐8.	  Identification	  of	  this	  problem	  has	  
been	  followed	  by	  an	  outpouring	  of	  concern	  from	  funding	  agencies	  such	  as	  the	  U.S.	  National	  
Institutes	  of	  Health9-­‐11	  and	  to	  an	  extent	  journals	  and	  professional	  bodies12-­‐17.	  	  	  
While	  much	  attention	  has	  been	  paid	  to	  the	  reproducibility	  of	  molecular	  assays,	  in	  vitro	  (cell	  
culture)	  assays	  and	  the	  inappropriate	  application	  of	  statistical	  methods	  (as	  well	  as	  simple	  
errors),	  only	  recently	  have	  the	  issues	  surrounding	  reproducibility	  in	  animal	  experimentation	  
been	  discussed	  in	  depth13.	  Much	  of	  these	  discussions	  have	  concerned	  husbandry	  and	  the	  effect	  
of	  diet	  and	  microbiome	  on	  experimental	  outcomes18-­‐20,	  particularly	  in	  neuroscience14,	  but	  
recent	  papers	  have	  addressed	  the	  problem	  of	  what	  a	  sound	  histopathological	  investigation	  
should	  look	  like,	  how	  to	  use	  knowledge	  of	  pathology	  in	  experimental	  design,	  based	  on	  the	  
ARRIVE	  and	  related	  guidelines,	  and	  more	  recently	  the	  confounding	  impact	  of	  the	  environment	  
and	  the	  gut	  and	  skin	  microbiomes5.	  	  
In	  this	  paper	  we	  address	  some	  of	  the	  issues	  impacting	  on	  the	  reproducibility	  of	  
histopathological	  findings:	  	  (1)	  lack	  of	  pathology	  expertise,	  in	  author	  lists	  and	  in	  peer-­‐review,	  (2)	  
poor	  standards	  of	  reporting—illustrated	  with	  common	  errors	  seen	  in	  papers—,	  and	  inconsistent	  
pathology	  nomenclature;	  and	  (3)	  availability	  of	  primary	  data,	  without	  which	  it	  is	  impossible	  to	  
assess	  a	  paper	  without	  attempting	  to	  undertake	  a	  compete	  experimental	  replication	  21-­‐23.	  Most	  
importantly,	  we	  emphasize	  that	  if	  pathologists	  are	  not	  involved	  in	  designing	  mouse	  
experiments	  and	  interpreting	  lesions,	  the	  accuracy	  of	  the	  diagnoses	  reported	  and	  conclusions	  
drawn	  may	  be	  questionable.	  	  
	  	  
The	  importance	  of	  pathologists	  
Investigators	  often	  do	  not	  have	  enough	  funds	  to	  pay	  for	  research	  pathology	  services	  and/or	  
believe	  that	  they	  can	  perform	  histopathology	  interpretations	  themselves.	  Pathology	  is	  a	  
medical	  specialty	  that	  requires	  years	  of	  training,	  experience,	  and	  board	  certification	  as	  a	  
minimum.	  Although	  pathology	  has	  many	  sub-­‐disciplines,	  such	  as	  mouse	  pathology,	  a	  general	  
pathologist	  is	  much	  more	  expert	  than	  a	  non-­‐pathologist,	  and	  is	  often	  sufficient	  to	  provide	  
substantial	  benefit	  to	  an	  animal	  research	  study24.	  Lack	  of	  pathology	  expertise	  by	  investigators	  
leads	  to	  inaccurate	  histopathological	  descriptions	  of	  lesions	  and	  often	  missed	  or	  spurious	  
reporting	  of	  pathologic	  findings	  in	  publications.	  Indications	  may	  be	  noticed	  in	  the	  figure	  legends	  
which	  often	  do	  not	  describe	  the	  lesions	  displayed,	  or	  in	  some	  rare	  cases	  images	  are	  replicated	  
in	  various	  orientations	  for	  different	  lesions	  or	  mice25.	  In	  some	  cases,	  a	  pathologist	  was	  not	  
involved	  in	  late	  or	  final	  edits	  or	  did	  not	  review	  the	  galley	  proofs	  of	  an	  accepted	  manuscript26.	  In	  
addition	  to	  accurate	  interpretation	  of	  data,	  pathologists	  are	  important	  to	  ensure	  proper	  
nomenclature	  is	  used	  when	  reporting	  on	  results.	  The	  use	  of	  generally	  accepted	  pathology	  
nomenclature	  for	  unexpected	  and	  novel	  findings	  leads	  to	  publications	  that	  can	  be	  interpreted	  
by	  readers,	  including	  other	  pathologists.	  Rodent	  pathology	  terminology	  often	  mirrors	  that	  used	  
for	  humans	  but	  differences	  do	  occur.	  Pathology	  of	  genetically	  engineered	  mice	  often	  requires	  
interpretation	  of	  novel	  findings	  since	  each	  mouse	  may	  have	  unique	  lesions	  not	  previously	  
reported,	  especially	  where	  the	  study	  is	  the	  first	  for	  a	  novel	  gene	  knockout	  or	  treatment.	  A	  
classic	  example	  is	  the	  relatively	  common	  lesion	  in	  mouse	  hearts	  that	  pathologists	  diagnose	  as	  
epicardial	  and	  myocardial	  mineralization	  and	  fibrosis	  but	  non-­‐pathologists	  often	  call	  
“dystrophic	  cardiac	  calcinosis”	  or	  a	  variety	  of	  other	  names27-­‐31.	  Investigators	  without	  pathology	  
backgrounds	  often	  over-­‐interpret	  their	  research	  findings,	  the	  temptation	  being	  to	  fit	  results	  to	  
their	  hypotheses.	  Over-­‐diagnosis	  of	  lesions	  as	  malignant	  when	  they	  may	  be,	  in	  fact,	  benign,	  
hyperplastic,	  or	  even	  normal	  is	  a	  common	  problem.	  This	  latter	  point	  emphasizes	  the	  value	  of	  
knowing	  anatomical	  differences	  between	  the	  species.	  	  
Some	  examples	  of	  errors	  seen	  in	  reported	  histopathological	  diagnoses	  	  
Besides	  incomplete	  reporting	  of	  the	  experimental	  design,	  including	  the	  pathology	  protocol,	  
there	  are	  common	  questionable	  diagnoses	  that	  can	  be	  found	  (Table	  1)	  32-­‐34.	  	  Often,	  the	  figure	  
legends	  do	  not	  describe	  what	  is	  illustrated	  by	  the	  figure,	  normal	  tissues	  are	  misidentified	  as	  
lesions,	  non-­‐neoplastic	  lesions	  are	  reported	  as	  cancer,	  or	  benign	  lesions	  are	  diagnosed	  as	  
malignant	  neoplasms.	  In	  addition,	  inflammatory	  lesions	  may	  be	  described	  as	  neoplasms	  or	  
“tumors”,	  benign	  or	  malignant.	  
Our	  interpretations	  of	  histopathology	  figures	  in	  published	  reports,	  which	  we	  will	  give	  as	  
examples,	  are	  based	  solely	  on	  our	  interpretation	  of	  what	  was	  present	  in	  the	  published	  figures	  
and	  not	  based	  on	  microscopic	  slide	  review.	  Slide	  review	  may	  reveal	  different	  findings	  than	  what	  
is	  in	  the	  published	  figures.	  Often	  the	  published	  histopathology	  figures	  are	  small	  and	  when	  
enlarged	  in	  the	  pdf	  file,	  they	  often	  lose	  resolution	  to	  the	  point	  of	  being	  uninterpretable.	  One	  of	  
many	  approaches	  to	  this	  problem	  is	  to	  post	  additional	  digital	  images	  at	  a	  variety	  of	  
magnifications	  or	  whole	  slide	  images	  as	  supplemental	  data	  and/or	  in	  other	  public	  websites	  such	  
the	  Mouse	  Tumor	  Biology	  Database	  (http://tumor.informatics.jax.org/mtbwi/index.do)35,	  36,	  
Gene	  Expression	  Database	  (http://www.informatics.jax.org/expression.shtml)37,	  Pathbase	  
(http://pathbase.net/)38,	  39,	  and	  many	  others5.	  	  	  
In	  order	  to	  evaluate	  any	  organs,	  such	  as	  skin,	  clear	  understanding	  of	  the	  normal	  anatomy	  is	  
absolutely	  necessary	  in	  order	  to	  recognize	  any	  type	  of	  change,	  be	  it	  disease	  or	  just	  subtle	  
changes	  in	  normal	  physiology.	  For	  the	  skin,	  a	  lack	  of	  knowledge	  of	  the	  normal	  hair	  cycle	  is	  a	  
commonly	  reported	  source	  of	  misinterpretation.	  All	  hair	  follicles	  regularly	  go	  through	  anagen,	  
the	  normal	  growth	  phase;	  catagen,	  the	  transition	  stage	  to	  telogen,	  the	  long	  term	  resting	  stage;	  
to	  exogen,	  when	  the	  old	  hair	  shaft	  is	  lost.	  This	  process	  then	  starts	  over	  again	  and	  is	  repeated	  
throughout	  life.	  The	  cycle	  varies	  by	  hair	  type	  (vibrissae	  cycle	  is	  different	  compared	  to	  body	  hair)	  
and	  species	  (mice	  cycle	  in	  waves	  while	  humans	  cycle	  in	  a	  mosaic	  pattern)1.	  The	  hypodermal	  fat	  
layer	  in	  the	  skin	  changes	  thickness	  through	  the	  cycle.	  When	  thinnest,	  in	  telogen40,	  this	  is	  often	  
reported	  as	  an	  abnormal	  phenotype.	  Sebaceous	  gland	  size	  also	  changes	  through	  the	  hair	  cycle	  
making	  estimation	  of	  the	  size	  of	  this	  gland	  an	  unpredictable	  feature,	  and	  also	  commonly	  
misinterpreted41.	  Changes	  in	  numbers	  of	  hair	  follicles	  can	  be	  misinterpreted	  owing	  to	  artifacts	  
of	  section	  orientation	  (Fig.	  2)42.	  
Male	  mice	  have	  modified	  sebaceous	  glands	  (with	  a	  large	  excretory	  duct	  along	  the	  penis)	  known	  
as	  preputial	  glands	  or	  clitoral	  glands	  in	  the	  inguinal	  area	  of	  females	  (Fig.	  3).	  These	  tissues	  have	  
been	  diagnosed	  as	  teratomas	  or	  skin	  tumors	  in	  some	  publications33,	  43,	  44,	  and	  an	  erratum	  
published	  for	  one	  of	  the	  publications43.	  Mouse	  accessory	  sex	  glands	  include	  various	  prostate	  
lobes,	  seminal	  vesicles,	  and	  other	  structures,	  the	  architecture	  of	  which	  differs	  from	  that	  of	  
humans.	  Tissue	  artifacts	  have	  been	  diagnosed	  as	  early	  stage	  prostate	  cancer45	  (Fig.	  4).	  	  
Immunohistochemistry	  findings	  are	  commonly	  a	  problem	  in	  publications.	  Authors	  often	  report	  
positive	  labeling	  (often	  with	  a	  brown	  chromogen)	  of	  cells	  and	  tissues	  which	  appear	  to	  represent	  
nonspecific	  background	  staining,	  due	  to	  omission	  of	  proper	  controls46.	  A	  good	  example	  was	  
reported	  in	  mouse	  prostate	  epithelial	  cells	  and	  connective	  tissue47	  using	  an	  anti-­‐human	  
antibody	  that	  never	  was	  reported	  (even	  by	  the	  company	  selling	  the	  antibody)	  to	  work	  in	  mouse	  
tissues.	  Mast	  cells	  are	  often	  nonspecifically	  positive	  in	  mouse	  tissues	  using	  peroxidase	  based	  
reagents48.	  	  	  	  
When	  is	  a	  neoplasm	  not	  a	  neoplasm?	  
Neoplasms	  and	  their	  preneoplastic/precancerous	  lesions	  are	  commonly	  found	  in	  mouse	  
experiments	  involving	  chemical	  carcinogens	  and/or	  in	  genetically	  engineered	  mice.	  The	  
majority	  of	  papers	  on	  mice	  with	  these	  induced	  or	  spontaneous	  lesions	  do	  not	  refer	  to	  the	  
publications	  that	  focus	  on	  standardized	  nomenclature	  for	  the	  organ	  or	  disease	  under	  
investigation	  such	  as	  those	  noted	  above	  and	  in	  our	  reference	  list.	  While	  many	  journals	  list	  in	  
their	  “instructions	  for	  authors”	  	  that	  they	  require	  authors	  to	  use	  standardized	  nomenclature,	  
this	  requirement	  is	  often	  not	  enforced	  by	  editors.	  This	  policy	  holds	  not	  only	  for	  diagnostic	  terms	  
but	  also	  for	  mouse	  strain	  and	  allele	  designations,	  as	  mouse	  genetic	  nomenclature	  is	  very	  
uniformly	  standardized49,	  50.	  The	  questionable	  diagnosis	  of	  preneoplastic	  and	  neoplastic	  lesions	  
of	  mice	  is	  commonly	  found	  in	  publications;	  some	  examples	  are	  given	  below.	  	  
The	  most	  widely	  used	  prostate	  cancer	  mouse	  model	  (commonly	  called	  TRAMP)	  is	  an	  example	  of	  
misuse	  of	  standardized	  nomenclature.	  A	  search	  of	  Mouse	  Genome	  Informatics	  
(http://www.informatics.jax.org/genes.shtml) yielded	  4	  matches	  (Table	  2),	  only	  one	  of	  which	  is	  
the	  transgenic	  line	  used	  for	  prostate	  cancer	  research	  (Tg(TRAMP08247Ng)51.	  With	  over	  600	  
publications,	  this	  transgenic	  line	  is	  often	  considered	  the	  best	  mouse	  model	  of	  human	  prostate	  
cancer.	  The	  Tg(TRAMP)08247Ng	  line	  was	  noted	  to	  have	  a	  high	  incidence	  of	  prostate	  
adenocarcinoma	  metastases	  suggesting	  that	  this	  was	  a	  good	  model	  for	  human	  prostate	  cancer.	  
However,	  these	  were	  later	  to	  shown	  to	  be	  of	  neuroendocrine	  origin	  and	  not	  of	  the	  typical	  
epithelial	  origin	  most	  common	  in	  humans	  (Fig.	  5)51-­‐53.	  Phylloides	  prostate	  carcinomas,	  initially	  
diagnosed	  in	  the	  first	  Tg(TRAMP)08247Ng	  publication,	  were	  later	  shown	  to	  be	  adenomas	  or	  
benign	  epithelial-­‐stromal	  tumors	  of	  the	  seminal	  vesicles	  (Fig.	  6)51,	  54.	  Metastatic	  prostate	  
carcinoma	  to	  bone	  marrow	  was	  described	  in	  a	  new	  genetically	  engineered	  mouse	  model	  but	  a	  
pathology	  nomenclature	  consensus	  committee	  determined	  that	  the	  cases	  were	  merely	  direct	  
invasion	  from	  a	  large	  prostate	  mass51,	  55.	  	  	  
Inflammatory	  lesions	  caused	  by	  bacteria	  have	  sometimes	  been	  reported	  as	  tumors	  
(neoplasms)56	  as	  have	  been	  other	  types	  of	  inflammation57.	  This	  may	  be	  technically	  correct,	  as	  
some	  textbooks	  define	  “tumor”	  literally	  as	  any	  type	  of	  swelling	  and	  one	  of	  the	  five	  cardinal	  
signs	  of	  inflammation,	  but	  inflammation	  should	  and	  can	  be	  easily	  differentiated	  from	  neoplasia.	  
Lymphomas	  and	  leukemias	  are	  often	  difficult	  to	  diagnose	  accurately.	  Tail	  tumors	  in	  transgenic	  
mice	  were	  reported	  to	  be	  large	  granular	  lymphocytic	  (LGL)	  leukemia58	  but	  other	  investigators	  
working	  with	  the	  same	  mice	  found	  sarcomas	  of	  various	  types	  including	  those	  arising	  in	  tendons	  
and	  nerves	  in	  the	  tail	  (Figs.	  7-­‐9).	  These	  tail	  tumors	  may	  have	  developed	  accompanying	  
inflammatory	  responses	  which	  included	  LGLs.	  Large	  spleens	  have	  been	  diagnosed	  as	  
myeloproliferative	  disorders	  and	  leukemias,	  especially	  in	  mice	  with	  ulcerative	  skin	  lesions	  which	  
cause	  reactive	  myeloid	  hyperplasia	  in	  the	  spleen	  of	  mice59.	  Using	  a	  Helicobacter	  felis	  mouse	  
gastric	  model,	  a	  research	  group	  developed	  a	  model	  of	  chronic	  gastritis	  that	  eventually	  was	  
reported	  to	  develop	  gastric	  lymphomas.	  These	  changes	  appeared	  histologically	  unconvincing	  as	  
the	  lesions	  described	  in	  the	  initial	  publication.	  However,	  in	  this	  case,	  a	  subsequent	  publication	  
did	  provide	  molecular	  proof	  that	  these	  were	  indeed	  lymphomas60.	  	  	  
How	  to	  increase	  reproducibility	  by	  improving	  nomenclature	  usage	  
Problems	  in	  pathology	  evaluation	  may	  occur	  at	  various	  stages	  of	  the	  study	  leading	  to	  
questionable	  pathology	  interpretation	  in	  the	  manuscript	  submitted	  or	  published.	  In	  order	  to	  
increase	  reproducibility	  in	  mouse	  studies,	  a	  trained	  pathologist	  knowledgeable	  in	  rodent	  
pathology	  nomenclature	  should	  be	  involved,	  either	  in	  study	  design,	  manuscript	  writing,	  or	  
chosen	  by	  editors	  during	  the	  peer-­‐review	  process.	  	  
Pathology	  nomenclature	  in	  the	  paper	  should	  follow	  general	  guidelines	  for	  mouse	  pathology	  as	  
published	  by	  international	  committees	  and	  experts,	  as	  discussed	  below.	  	  
The	  ability	  of	  a	  pathologist	  to	  accurately	  diagnose	  lesions	  in	  laboratory	  animals,	  especially	  
rodents,	  depends	  on	  training	  and	  experience.	  Experience	  includes	  the	  use	  of	  widely	  acceptable	  
veterinary	  pathology	  and	  species	  specific	  nomenclature	  often	  provided	  through	  publications	  by	  
expert	  groups	  of	  pathologists	  and	  by	  international	  or	  national	  committees33,	  61-­‐65	  and	  in	  books	  
with	  multiple	  authors61,	  66-­‐69.	  Also	  others	  have	  proposed	  formal	  ontologies	  for	  data	  capture	  and	  
analysis39,	  70,	  71,	  which	  are	  also	  based	  on	  international	  nomenclatures	  and	  informatics	  standards.	  	  
There	  are	  numerous	  publications	  on	  neoplastic	  diseases	  in	  mice,	  especially	  in	  genetically	  
engineered	  mice	  (GEM).	  The	  NCI	  Mouse	  Models	  of	  Human	  Cancer	  Consortium	  over	  the	  past	  15	  
years	  has	  established	  pathology	  committees	  to	  develop	  nomenclatures	  for	  several	  important	  
organs33,	  51,	  61.	  The	  publications	  on	  neoplastic	  diseases	  in	  mammary	  gland,	  prostate,	  lung,	  
intestine,	  brain,	  skin	  and	  pancreas	  provide	  important	  guidelines	  for	  investigators	  
(http://emice.nci.nih.gov/camod-­‐models-­‐by-­‐organ-­‐site).	  The	  INHAND	  pathology	  nomenclatures	  
have	  similarly	  created	  detailed	  terminological	  recommendations	  for	  both	  proliferative	  and	  non-­‐
proliferative	  lesions	  under	  the	  auspices	  of	  the	  committees	  established	  by	  a	  consortium	  of	  
societies	  of	  toxicologic	  pathology,	  which	  can	  be	  found	  on	  https://www.toxpath.org/inhand.asp.	  
These,	  together	  with	  detailed	  publications	  on	  individual	  classes	  of	  lesion	  make	  up	  a	  significant	  
terminological	  corpus	  and	  pathologists	  making	  diagnoses	  should	  be	  familiar	  with	  these.	  
	  
	  Conclusion	  
In	  comparison	  to	  factors	  confounding	  reproducibility	  of	  mouse	  biological	  experiments	  
originating	  in	  experimental	  design,	  husbandry,	  and	  microbiome,	  the	  problem	  of	  reliable	  
histopathological	  interpretation	  of	  experimental	  animals	  is	  perhaps	  one	  of	  the	  most	  tractable	  
sources	  of	  error.	  Enrolment	  of	  an	  experienced	  pathologist	  onto	  a	  study	  early	  in	  its	  inception	  
and	  planning	  stages,	  then	  its	  subsequent	  analysis,	  is	  clearly	  highly	  desirable,	  and	  many	  of	  the	  
problems	  we	  discuss	  above	  are	  unlikely	  to	  arise	  under	  the	  guidance	  of	  appropriately	  trained	  
personnel.	  The	  issue	  of	  finding	  experienced	  mouse	  pathologists	  is	  one	  which	  has	  been	  
discussed	  at	  length	  elsewhere2,	  24,	  34,	  though	  the	  authors	  feel	  that	  the	  mouse	  pathology	  
community	  is	  sufficiently	  interactive	  that	  good	  advice	  can	  easily	  be	  sought	  out	  by	  motivated	  
investigators.	  	  
Changes	  in	  priorities	  at	  journals	  and	  funding	  agencies	  are	  also	  needed	  to	  significantly	  improve	  
the	  reliability	  of	  pathology	  in	  mouse	  model	  studies.	  Availability	  of	  the	  primary	  images	  on	  which	  
experimental	  conclusions	  are	  based	  should	  be	  mandatory	  at	  journals	  and	  in	  line	  with	  the	  FAIR	  
guidelines5,72.	  Similarly,	  funding	  agencies	  need	  to	  pay	  more	  attention	  to	  the	  intended	  use	  of	  
histopathology	  in	  grant	  applications	  and	  insist	  on	  provision	  of	  appropriate	  expertise	  with	  an	  
appropriate	  budget.	  Increased	  stringency	  surrounding	  the	  processes	  of	  funding	  and	  publication	  
might	  represent	  more	  effort	  for	  researchers,	  reviewers,	  and	  journal	  editors,	  but	  will	  reduce	  the	  
instances	  of	  flawed	  histopathology	  we	  see	  in	  many	  journals	  today.	  The	  pragmatic	  answer	  has	  to	  
be	  the	  education	  of	  investigators	  in	  the	  critical	  assessment	  of	  histopathology	  data,	  but	  in	  the	  







FIGURE1 Numbers of papers published between 1948 and 2015 indexed in Pubmed as 
(red squares) "Mouse histopathology", and (blue diamonds), "Mouse model." (data 
accessed 12.9.16)	  
 
FIGURE 2 Skin of mouse in anagen with abundant hair follicles. 	  
This normal stage of the cell cycle has been reported to be hyperplasia. H&E, X10.	  
	  
FIGURE 3 Normal mouse preputial gland showing glandular tissue with central ducts.	  
Two publications reported normal glands as teratomas or carcinomas. H&E, X4.	  
	  
FIGURE 4 Normal prostate of young mouse with artefactual folds of the acinar 
epithelium which were misdiagnosed as early stage prostate cancer in a publication. 
H&E, X40. 	  
	  
FIGURE 5 Neuroendocrine carcinoma in the prostate of a TRAMP 
(Tg(TRAMP)8247Ng) mouse. These mice were reported to develop highly metastatic 
prostate adenocarcinoma.  H&E, X40. 	  
	  
FIGURE 6  Benign (epithelial-stromal) tumor in the seminal vesicles of a TRAMP 
mouse. Note tumor growth into the lumen and no invasion. These lesions were reported 
as phylloides prostate carcinomas.	  H&E, X4. 	  
	  
FIGURE 7  Tail of a HTLV-I  tax transgenic mouse with early tumors (on left and right 
side) of tendon origin. This mouse was reported to develop leukemia and not tendon 
tumors. H&E, X4. 	  
	  
FIGURE  8  Tail of a HTLV-I tax transgenic mouse with an early tumor of tail tendon 
origin (darker tumor in the lower portion of the figure beneath the skin). This mouse was 
reported to develop leukemia. H&E, X4.	  
 
FIGURE 9  Early tail tendon sarcoma showing tumor infiltration by myeloperoxidase 
positive neutrophils. Immunoperoxidase, X40.  
	  
TABLE 1 Evidence of Questionable Pathology Interpretation in Publications 
Figure legends do not accurately reflect what is in the figure 
Figure legends do not describe anything in the figure 
Lack of complete or appropriate necropsies and histopathology 
Misidentification of normal organs and tissues as lesions    
Diagnoses of non-neoplastic lesions as neoplasms 
Diagnoses of tumors with unconventional terminology 
Reporting of benign lesions as malignant 
Reporting of inflammatory lesions as tumors 
Reporting of novel lesions incorrectly 
Use of incorrect (accepted) terminology/diagnoses 
	  
TABLE 2. Partial table from Mouse Genome Informatics (Accessed 19 Sept. 2016) to 
illustrate three genes and one transgene identified by the term TRAMP, three of which are 
unrelated genes. Source: http://www.informatics.jax.org/genes.shtml	  
Genetic 
Location	  
Symbol	   Why Matched	  
Chr4 82.89 cM	   Tnfrsf25, tumor necrosis factor receptor 




Chr1 4.18 cM	   Tram1, translocating chain-associating 




Chr Unknown	   Tg(TRAMP)8247Ng, transgene insertion 8247, 
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